Literature DB >> 16585276

Urine interleukin-8 as a marker of vesicoureteral reflux in infants.

Emmanouil Galanakis1, Maria Bitsori, Helen Dimitriou, Christina Giannakopoulou, Nikolaos S Karkavitsas, Maria Kalmanti.   

Abstract

OBJECTIVE: Vesicoureteral reflux (VUR) is a common finding in children presenting with urinary tract infection (UTI) and prenatally diagnosed urinary tract dilatation and in relatives of index patients. Children with VUR are at risk for ongoing renal damage with subsequent infections. Detecting VUR and renal scarring currently depends on imaging modalities with associated problems of radiation, invasiveness, and expense. Noninvasive methods would greatly facilitate diagnosis and would also help in identifying relatives of index cases who should be screened. Interleukin-8 (IL-8) is produced by epithelial cells of the renal tract in response to inflammatory stimuli and has been shown to increase during acute UTI. The objective of this study was to assess the urine levels of IL-8 as a noninvasive marker of VUR in infants in the absence of a recent UTI episode.
METHODS: We evaluated urine concentrations of IL-8 in 59 infants aged 1 month to 2 years. All infants were free of UTI for a minimum of 3 weeks before IL-8 evaluation. Infants were divided into 3 groups: group A, subjects with proven VUR (24 infants aged 0.15-1.95 years, median 0.43); group B, subjects with a history of UTI but negative investigation for VUR (14 infants aged 0.32-1.95 years, median 0.57); and group C, subjects without any history of acute or chronic condition that might impair renal function (21 infants aged 0.08-1.92 years, median 0.33). IL-8 concentrations were determined by a commercially available quantitative enzyme-linked immunosorbent assay. To avoid dilution effects, urinary levels of IL-8 were expressed as the ratio of cytokine-to-urinary creatinine.
RESULTS: Results were presented as medians and ranges. The Kruskal-Wallis test, the Mann-Whitney rank sum U test, and the Spearman rank order correlation test were performed for the univariate analysis. Two-tailed P values were calculated and the conventional level of significance P < .05 was applied in all cases. Infants in groups A and B had been free of UTI for a period of 3 to 52 weeks (median, 5.0 weeks) and 3 to 78 weeks (median, 4.5 weeks), respectively, before IL-8 determination. No significant difference was noted in the length of the UTI-free period between groups A and B (P = .469). Urine creatinine concentrations did not differ among groups A, B, and C (medians 1.15, 2.25, and 1.15 micromol/mL, respectively; P = .080). The median urine IL-8/creatinine concentrations (pg/micromol) were 40.5 (range, 2.04-3874) in group A, 1.91 (range, 0.001-386) in group B, and 2.47 (range, 0.002-55.6) in group C. Urine IL-8/creatinine concentrations were significantly higher in group A than both in group B (P = .0003) and in group C (P < .0001). No significant difference was observed between groups B and C (P = .749). In group A, no significant correlation was shown between IL-8/creatinine concentrations and the presence of renal parenchymal damage (P = .506), reflux grade (P = .770), or time from UTI (P = .155). A receiver-operator characteristic curve was constructed by plotting the sensitivity versus the specificity for different cutoff concentrations of IL-8/creatinine. With a cutoff concentration of urinary IL-8/creatinine at 5 pg/micromol, the sensitivity of this marker in diagnosing VUR was 88%, the specificity 69%, the positive prognostic value 66%, and the negative prognostic value 89%. In higher cutoff concentrations, specificity of the marker increased but sensitivity rapidly decreased.
CONCLUSIONS: We present evidence that urine IL-8 concentrations remain elevated in infants with VUR even in the absence of UTI and that a cutoff of 5 pg/micromol IL-8/creatinine is of high sensitivity and adequate specificity for diagnosing VUR. Elevated urine IL-8 levels in VUR and renal scarring have already been reported; however, the present study is, to our knowledge, the first to confirm significant differences between infants with VUR and infants with a history of UTI alone and healthy controls, and to suggest a reliable cutoff concentration for diagnosing VUR. Our findings additionally suggest that inflammatory process in VUR is ongoing even after UTI has resolved, pointing against the currently held belief that sterile reflux cannot harm kidneys. The chronic inflammatory cell infiltrate associated with reflux nephropathy rather than VUR itself might offer an explanation for the secretion of IL-8, which may well be independent of reflux grade. Using urine IL-8 for diagnosing VUR is not free of limitations, because IL-8 may be elevated as a result of urinary tract manipulation or undetected UTI. In addition, this study focused on infants and not in older children with longstanding VUR. Increased urine IL-8 concentrations after UTI has resolved is a promising noninvasive marker for an initial screening for VUR in infancy with high sensitivity and adequate specificity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16585276     DOI: 10.1542/peds.2005-2051

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  15 in total

1.  Urine IL-8 concentrations in infectious and non-infectious urinary tract conditions.

Authors:  Maria Bitsori; Maria Karatzi; Helen Dimitriou; Eleni Christakou; Avrora Savvidou; Emmanouil Galanakis
Journal:  Pediatr Nephrol       Date:  2011-05-21       Impact factor: 3.714

2.  Cytokines in chronic kidney disease: potential link of MCP-1 and dyslipidemia in glomerular diseases.

Authors:  Heloisa Reniers Vianna; Cristina Maria Bouissou M Soares; Katia Daniela Silveira; Gustavo Siqueira Elmiro; Philipe Melgaço Mendes; Marcelo de Sousa Tavares; Mauro Martins Teixeira; Débora Marques Miranda; Ana Cristina Simões E Silva
Journal:  Pediatr Nephrol       Date:  2012-11-18       Impact factor: 3.714

3.  Posterior urethral valve in fetuses: evidence for the role of inflammatory molecules.

Authors:  Érica Leandro Marciano Vieira; Natalia Pessoa Rocha; Fernando Macedo Bastos; Kátia Daniela da Silveira; Alamanda K Pereira; Eduardo Araújo Oliveira; Débora Marques de Miranda; Ana Cristina Simões E Silva
Journal:  Pediatr Nephrol       Date:  2017-02-22       Impact factor: 3.714

4.  Interleukin 8 (IL-8) - a universal biomarker?

Authors:  Aamir Shahzad; Martin Knapp; Irene Lang; Gottfried Köhler
Journal:  Int Arch Med       Date:  2010-06-15

5.  Interleukin-6 and interleukin-8 levels in the urine of children with renal scarring.

Authors:  Despoina Tramma; Maria Hatzistylianou; George Gerasimou; Vasilis Lafazanis
Journal:  Pediatr Nephrol       Date:  2012-04-24       Impact factor: 3.714

6.  Urinary levels of TGF β-1 and of cytokines in patients with prenatally detected nephrouropathies.

Authors:  Mariana A Vasconcelos; Maria Candida F Bouzada; Katia D Silveira; Leticia R Moura; Fabiana F Santos; Juliana M Oliveira; Flavia F Carvalho; Mauro M Teixeira; Ana Cristina Simões E Silva; Eduardo A Oliveira
Journal:  Pediatr Nephrol       Date:  2011-02-18       Impact factor: 3.714

7.  Urinary levels of interleukin-6 and interleukin-8 in patients with vesicoureteral reflux and renal parenchymal scar.

Authors:  Ibrahim Gokce; Harika Alpay; Nese Biyikli; Goksenin Unluguzel; Fuat Dede; Ahmet Topuzoglu
Journal:  Pediatr Nephrol       Date:  2010-05       Impact factor: 3.714

8.  Lack of association of IL8 gene polymorphisms with familial vesico-ureteral reflux.

Authors:  Seika Kuroda; Prem Puri
Journal:  Pediatr Surg Int       Date:  2007-05       Impact factor: 2.003

Review 9.  Interactions between cytokines, congenital anomalies of kidney and urinary tract and chronic kidney disease.

Authors:  Ana Cristina Simões e Silva; Flávia Cordeiro Valério; Mariana Affonso Vasconcelos; Débora Marques Miranda; Eduardo Araújo Oliveira
Journal:  Clin Dev Immunol       Date:  2013-08-26

Review 10.  Chemokines as potential markers in pediatric renal diseases.

Authors:  Ana Cristina Simões e Silva; André Barreto Pereira; Mauro Martins Teixeira; Antônio Lúcio Teixeira
Journal:  Dis Markers       Date:  2014-02-17       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.